MarketPulse

CAR T-cell therapy

6 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Cormorant's $64M Arcellx Exit Preceded 77% Gilead Takeover Surge

Cormorant Asset Management exited its $63.63M Arcellx stake in Q4, missing an 80% year-to-date rally capped by Gilead Sciences' $7.8B acquisition announcement.
GILDACLXfund exitoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tempest Advances CAR-T Program With Manufacturing Deal Ahead of 2026 FDA Filing

Tempest Therapeutics partners with Cincinnati Children's for TPST-2003 manufacturing, targeting U.S. registrational study launch in 2026 following strong interim trial results.
TPSTclinical trialmultiple myeloma
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Bristol Myers' Abecma Poised for Explosive Growth as CAR-T Therapy Expands Beyond Relapsed Myeloma

Abecma CAR-T therapy market surging on rising myeloma cases and regulatory wins. BMS-backed treatment faces headwinds from tariffs but eyes earlier-line expansion.
BMYCELGrregulatory approvalmultiple myeloma
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lyell Immunopharma Secures $50M Funding Tranche on Clinical Progress

Lyell Immunopharma closes $50M funding tranche, advances ronde-cel in pivotal lymphoma trial, appoints new CFO with extended cash runway through Q2 2027.
LYELCAR T-cell therapycash runway
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyverna Bolsters Board With Beam, Karuna Executives Ahead of Cell Therapy Launch

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.
BMYCELGrKYTXBEAMclinical developmentautoimmune diseases
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Arcellx for $7.8B to Expand CAR-T Oncology Portfolio

Gilead acquires Arcellx for $7.8B to gain CAR-T therapy anito-cel for multiple myeloma, with FDA approval expected by late 2026.
GILDACLXacquisitionFDA approval